| Shareholders Alert: Investigation Into Organon & Co. (OGN) - Contact Levi & Korsinsky to Protect Your Rights |
NEW YORK, NY / ACCESS Newswire / May 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-16 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-16 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Launches Fraud Investigation on Behalf of Organon & Co. (OGN) Shareholders |
NEW YORK, NY / ACCESS Newswire / May 15, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-15 14:30:00 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-15 14:00:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Organon & Co. (OGN) Over Possible Securities Fraud |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-15 01:20:00 |
Czytaj oryginał (ang.) |
| Levi & Korsinsky Investigates Organon & Co. (OGN) Over Possible Securities Fraud |
NEW YORK, NY / ACCESS Newswire / May 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-14 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Investors to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-14 14:00:00 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights |
NEW YORK, NY / ACCESS Newswire / May 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-13 14:15:00 |
Czytaj oryginał (ang.) |
| Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy |
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration. |
seekingalpha.com |
2025-05-12 15:47:04 |
Czytaj oryginał (ang.) |
| Organon & Co. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - OGN |
NEW YORK, NY / ACCESS Newswire / May 12, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-12 14:15:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Organon & Co. (OGN) and Encourages Investors to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-12 14:00:00 |
Czytaj oryginał (ang.) |
| Shareholders that lost money on Organon & Co.(OGN) should contact Levi & Korsinsky about Securities Fraud Investigation - OGN |
NEW YORK, NY / ACCESS Newswire / May 11, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-11 15:00:00 |
Czytaj oryginał (ang.) |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Organon & Co. (OGN) And Encourages Stockholders to Connect |
NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE: OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-11 14:00:00 |
Czytaj oryginał (ang.) |
| Organon & Co. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - OGN |
NEW YORK, NY / ACCESS Newswire / May 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-10 22:01:00 |
Czytaj oryginał (ang.) |
| OGN INVESTIGATION NOTICE: Investigation Launched into Organon & Co. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm |
SAN DIEGO , May 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the Organon investigation or if you are an Organon investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-organon-co-investigation-ogn.html You can also contact attorneys J.C. |
prnewswire.com |
2025-05-10 14:40:00 |
Czytaj oryginał (ang.) |
| OGN STOCK ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-09 14:30:00 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation |
NEW YORK CITY, NY / ACCESS Newswire / May 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Organon & Co. ("Organon" or "the Company") (NYSE:OGN). Investors who purchased Organon securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/OGN. |
accessnewswire.com |
2025-05-09 14:00:00 |
Czytaj oryginał (ang.) |
| OGN STOCK ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of an Ongoing Investigation |
NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Organon & Co. ("Organon & Co.") (NYSE:OGN) concerning possible violations of federal securities laws. On May 1, 2025, Organon reported mixed Q1 FY25 results, missing expectations on revenue decline of 7% y/y to $1.51B. |
accessnewswire.com |
2025-05-09 01:20:00 |
Czytaj oryginał (ang.) |
| ORGANON ALERT: Bragar Eagel & Squire, P.C. is Investigating Organon & Co. on Behalf of Organon Stockholders and Encourages Investors to Contact the Firm |
NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Organon & Co. (“Organon” or the “Company”) (NYSE:OGN) on behalf of Organon stockholders. Our investigation concerns whether Organon has violated the federal securities laws and/or engaged in other unlawful business practices. |
globenewswire.com |
2025-05-09 01:00:00 |
Czytaj oryginał (ang.) |
| Organon: Management Slashes Dividend - This Feels Disastrous |
Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its Established Brands division, exacerbated by the patent expiry of key drugs. Management's rationale for cutting the dividend to manage debt and pursue M&A opportunities appears flawed, as it fails to address core financial issues. |
seekingalpha.com |
2025-05-08 15:08:06 |
Czytaj oryginał (ang.) |
| High-Yield Healthcare: 3 Stocks With Strong Dividends |
When it comes to dividend performers, healthcare usually takes a backseat to options like REITs and energy stocks. However, the sector's resilience, driven by aging populations and consistent demand for medical services, makes it an underrated source of steady income. |
marketbeat.com |
2025-02-16 09:16:00 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Q4 2024 Earnings Call Transcript |
Organon & Co. (NYSE:OGN ) Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Terence Flynn - Morgan Stanley Michael Nedelcovych - TD Cowen Ethan Brown - JPMorgan David Amsellem - Piper Sandler Balaji Prasad - Barclays Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Celine and I will be your conference operator today. |
seekingalpha.com |
2025-02-13 14:47:18 |
Czytaj oryginał (ang.) |
| Organon (OGN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates |
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2025-02-13 13:31:15 |
Czytaj oryginał (ang.) |
| Organon (OGN) Q4 Earnings and Revenues Beat Estimates |
Organon (OGN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.86 per share. This compares to earnings of $0.88 per share a year ago. |
zacks.com |
2025-02-13 11:46:13 |
Czytaj oryginał (ang.) |
| Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024 |
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon announces Q4 2024 and Full Year 2024 earnings results, ending December 31, 2024. |
businesswire.com |
2025-02-13 09:30:00 |
Czytaj oryginał (ang.) |
| Why Organon (OGN) Dipped More Than Broader Market Today |
Organon (OGN) concluded the recent trading session at $14.62, signifying a -1.81% move from its prior day's close. |
zacks.com |
2025-02-07 20:50:17 |
Czytaj oryginał (ang.) |
| Organon (OGN) Rises Higher Than Market: Key Facts |
The latest trading day saw Organon (OGN) settling at $15.97, representing a +0.82% change from its previous close. |
zacks.com |
2025-01-30 20:56:30 |
Czytaj oryginał (ang.) |
| Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know |
Organon (OGN) closed at $16.26 in the latest trading session, marking a +1.82% move from the prior day. |
zacks.com |
2025-01-27 21:06:20 |
Czytaj oryginał (ang.) |
| Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025 |
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025. |
businesswire.com |
2025-01-23 09:30:00 |
Czytaj oryginał (ang.) |
| Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing |
Organon (OGN) closed the most recent trading day at $15.88, moving +0.89% from the previous trading session. |
zacks.com |
2025-01-21 21:05:28 |
Czytaj oryginał (ang.) |
| Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield |
Organon has faced significant price volatility and underperformance since its spin-off from Merck, with shares down ~50% since 2021. Key products like Nexplanon and VTAMA are crucial for future growth, but uncertainties and competition pose significant risks to revenue projections. Organon's high debt and interest payments are significant concerns, despite low P/S and P/E ratios suggesting undervaluation, and a strong dividend yield. |
seekingalpha.com |
2025-01-17 15:03:31 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) JPMorgan Annual Healthcare Conference - (Transcript) |
Organon & Co. (NYSE:OGN ) JPMorgan Annual Healthcare Conference Call January 13, 2025 6:45 PM ET Company Participants Kevin Ali - Chief Executive Officer Matthew Walsh - Chief Financial Officer Conference Call Participants Chris Schott - JPMorgan Chris Schott Good afternoon, everybody. I'm Chris Schott from JPMorgan and it's my pleasure to be hosting this fireside chat with the Organon management team. |
seekingalpha.com |
2025-01-13 23:38:25 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2025-01-01 12:01:20 |
Czytaj oryginał (ang.) |
| Want $2,000 in Annual Dividends? Invest $11,000 in Each of These 3 Stocks. |
Investing in dividend stocks can be an excellent way to boost your income each year. But the challenge can be generating a good return while keeping your risk low. |
fool.com |
2025-01-01 09:55:00 |
Czytaj oryginał (ang.) |
| Organon (OGN) Ascends While Market Falls: Some Facts to Note |
Organon (OGN) closed at $15.06 in the latest trading session, marking a +0.74% move from the prior day. |
zacks.com |
2024-12-27 20:56:22 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know |
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects. |
zacks.com |
2024-12-20 12:00:38 |
Czytaj oryginał (ang.) |
| Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference |
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon CEO Kevin Ali and CFO Matthew Walsh to present in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th. |
businesswire.com |
2024-12-19 09:30:00 |
Czytaj oryginał (ang.) |
| Organon price target raised to $20 from $19 at Goldman Sachs |
Goldman Sachs raised the firm's price target on Organon to $20 from $19 and keeps a Neutral rating on the shares. The firm cites the company's announced FDA approval of VTAMA for the topical treatment of atopic dermatitis, or AD, in adults and pediatric patients 2 years of age and older. VTAMA's AD approval addresses multiple unmet needs in the atopic dermatitis market previously demonstrated by their Phase 3 results, though the firm expects successful launch will require a heightened level of investment in sales/marketing support given the primary care dimensions of the AD market, the analyst tells investors in a research note. |
https://thefly.com |
2024-12-17 19:42:00 |
Czytaj oryginał (ang.) |
| Final Trades: Amazon, American Express and Organon |
The CNBC 'Halftime Report' Investment Committee give their top stocks to watch for the second half. |
youtube.com |
2024-12-10 15:40:22 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It |
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2024-12-09 12:00:39 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know |
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-11-26 12:00:31 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It |
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock. |
zacks.com |
2024-11-15 12:01:17 |
Czytaj oryginał (ang.) |
| Organon: 7% Yield, 4x P/E, Big Upside Potential |
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has shown steady performance with growth in adjusted EBITDA and free cash flow. The acquisition of Dermavant and its promising treatment VTAMA for psoriasis and atopic dermatitis could be transformative, expanding OGN's reach into high-demand areas. |
seekingalpha.com |
2024-11-14 14:42:51 |
Czytaj oryginał (ang.) |
| Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) |
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue growth, driven by strong volume growth more than offsetting pricing weakness and currency headwinds. The $1.2 billion Dermavant acquisition appears strategically acceptable but carries significant risks due to market competition and OGN's high debt. |
seekingalpha.com |
2024-11-13 10:30:00 |
Czytaj oryginał (ang.) |
| Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know |
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store. |
zacks.com |
2024-11-04 12:00:21 |
Czytaj oryginał (ang.) |
| Organon & Co. (OGN) Q3 2024 Earnings Call Transcript |
Organon & Co. (NYSE:OGN ) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Walsh - CFO Conference Call Participants Balaji Prasad - Barclays David Amsellem - Piper Sandler Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Operator Thank you for standing by. My name is Mandeep and I'll be your operator today. |
seekingalpha.com |
2024-10-31 14:28:12 |
Czytaj oryginał (ang.) |
| Organon (OGN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates |
The headline numbers for Organon (OGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals. |
zacks.com |
2024-10-31 13:30:16 |
Czytaj oryginał (ang.) |
| Organon (OGN) Q3 Earnings and Revenues Beat Estimates |
Organon (OGN) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.87 per share a year ago. |
zacks.com |
2024-10-31 11:46:11 |
Czytaj oryginał (ang.) |
| Organon Reports Results for the Third Quarter Ended September 30, 2024 |
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings. |
businesswire.com |
2024-10-31 09:30:00 |
Czytaj oryginał (ang.) |
| Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics |
Evaluate the expected performance of Organon (OGN) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight. |
zacks.com |
2024-10-28 12:21:36 |
Czytaj oryginał (ang.) |
| Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1% |
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%. |
businesswire.com |
2024-10-28 11:25:00 |
Czytaj oryginał (ang.) |
| Earnings Preview: Organon (OGN) Q3 Earnings Expected to Decline |
Organon (OGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-24 15:06:01 |
Czytaj oryginał (ang.) |